Most Read Articles
Rachel Soon, 16 Aug 2019

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.

Metformin does not prevent cancer in diabetic patients

10 Aug 2019

Treatment with metformin does not appear to provide an additional benefit of reducing the incidence of cancers, excluding those of the prostate and pancreas, in patients with diabetes, as reported in a study.

Researchers looked at a cohort of 315,890 incident diabetic individuals aged 21–87 years, among whom 304,582 had no previous diagnosis of cancer. More than half of the population (n=172,948; 54.7 percent) took metformin at some time during their follow-up.

Weighted cumulative metformin exposure was evaluated in relation to cancer incidence using a time-dependent covariate Cox model, which was controlled for treatments with other glucose lowering medications, as well as age, sex, ethnic background, socioeconomic status, smoking (for bladder and lung cancer) and parity (for breast cancer). Metformin exposure in the year before cancer diagnosis was excluded in the analysis to minimize reverse causation of cancer on changes in medication.

Results showed no clear association between the use of metformin and all-sites cancer (excluding prostate and pancreas), and cancers of the colon, breast, lung and bladder. The hazard ratios with exposure to one defined daily dose of metformin over the previous 2–7 years were 0.98 (95 percent CI, 0.82–1.18) for all-sites cancer (excluding prostate and pancreas), 1.05 (0.67–1.63) for colon cancer, 0.98 (0.49–1.97) for bladder cancer, 1.02 (0.59–1.78) for lung cancer and 0.88 (0.56–1.39) for female breast cancer.

The study was limited by reliance on medication purchase data to identify medication use, relatively short study duration, and lack of data on confounding risk factors for cancer.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 16 Aug 2019

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.